Validation and 3 years of clinical experience in using an AI algorithm as a second read system for prostate cancer diagnosis

Prostate cancer ranks as the most frequently diagnosed cancer in men in the USA, with significant mortality rates. Early detection is pivotal for optimal patient outcomes, providing increased treatment options and potentially less invasive interventions.

Click to access the full article

• 

  CorePlus and Ibex show real world success with AI for routine cancer diagnosis

  CorePlus and Ibex show real world success with AI for routine cancer diagnosis.

  Publications

• 

  ArteraAI Announces Research Agreement with CorePlus

  ArteraAI, a developer of AI-based cancer tests, has partnered with CorePlus, a CLIA-certified pathology laboratory in Puerto Rico.

  Publications

• 

  CorePlus Expands Use of AI Tools to Routine Cancer Diagnosis

  Back in June 2020, CorePlus Servicios Clínicos y Patológicos LLC (Carolina, Puerto Rico) became the first independent lab in the…

  Publications